Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Intranasal COVID-19 vaccines: From bench to bed

(2022) Aqu Alu et al.   EBioMedicine

Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans

(2022) Mangalakumari Jeyanathan et al.   JCI Insight

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials

(2022) Fengcai Zhu et al.   Lancet Respiratory Medicine

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

(2022) Jing-Xin Li et al.   Lancet Respiratory Medicine

Differential Biodistribution of Adenoviral-Vectored Vaccine Following Intranasal and Endotracheal Deliveries Leads to Different Immune Outcomes

(2022) Vidthiya Jeyananthan et al.   Frontiers in Immunology

SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals

(2022) Kaori Sano et al.   Nature Communications

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

(2021) Andreas Greinacher et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery

(2021) Apoorva Mulay et al.   Cell Reports

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

(2021) Shipo Wu et al.   LANCET INFECTIOUS DISEASES

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

(2021) Neeltje van Doremalen et al.   Science Translational Medicine

Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19

(2021) James P Bridges et al.   THORAX

Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis

(2021) Giulia Perego et al.   Vaccines

Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs

(2021) Carina C. D. Joe et al.   BIOTECHNOLOGY AND BIOENGINEERING

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

(2021) Dennis Lapuente et al.   Nature Communications

The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines

(2021) Renee W. Y. Chan et al.   Frontiers in Immunology

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

(2021) Lorenzo Azzi et al.   EBioMedicine

Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study

(2020) David Liebowitz et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

(2020) Neeltje van Doremalen et al.   NATURE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Enhanced SARS-CoV-2 neutralization by dimeric IgA

(2020) Zijun Wang et al.   Science Translational Medicine

IgA dominates the early neutralizing antibody response to SARS-CoV-2

(2020) Delphine Sterlin et al.   Science Translational Medicine

Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels

(2015) Marloes Vissers et al.   Clinical and Vaccine Immunology

Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults

(2015) Bindiya Bagga et al.   JOURNAL OF INFECTIOUS DISEASES

Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus

(2015) Tadaki Suzuki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mucosal vaccination by adenoviruses displaying reovirus sigma 1

(2015) Eric A. Weaver et al.   VIROLOGY

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice

(2015) Matthew D. J. Dicks et al.   Scientific Reports

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults

(2015) C A Green et al.   BMJ Open

Secretory IgA: Designed for Anti-Microbial Defense

(2013) Per Brandtzaeg   Frontiers in Immunology